Abstract
AbstractAcetazolamide is a carbonic anhydrase inhibitor whose primary indication is to alleviate altitude sickness, but it is also used in the treatment of glaucoma, seizures and oedema. Although it has not been repurposed for psychiatric illnesses, acetazolamide has been advocated for its putative benefits in those with a bipolar disorder (BD). Because current treatment options for BD bring a variety of challenges, it is important to examine the current evidence to date in a formal synthesis. This article describes a protocol for a scoping review to do so, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews (PRISMA-ScR). PubMed, Embase and PsycInfo will be searched for all available publications focusing on the intervention acetazolamide for people with BD. This will include non-primary and primary research of any design, focusing on any outcome, in order to comprehensively bring together the work that has been undertaken to date on this topic. Relevant data from included articles will be subject to a narrative synthesis. It is anticipated that the results from the review will help to ascertain the potential for acetazolamide to benefit people with bipolar affective disorders in the future and aid the planning of future primary research to establish this.
Publisher
Cold Spring Harbor Laboratory
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献